Loading stock data…
$5.11-0.42 (-7.59%)
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
Adicet Bio, Inc. in the Healthcare sector is trading at $5.11 with a market capitalization of $89M. Wall Street consensus targets $34.83 (6 analysts), implying a +581.7% move over the next 12 months. The stock is currently near its 52-week low of $5.10, remaining 35.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.30M↓ | -$21.57M↑ | -$31.89M↓ | -$27.95M↑ | -$32.39M |
| Net Income | -$21.36M↓ | -$20.24M↑ | -$30.52M↓ | -$26.86M↑ | -$31.22M |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel),...